| Name | Title | Contact Details |
|---|
Catalyst Biosciences is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in South San Francisco, CA. To find more information about Catalyst Biosciences, please visit www.catbio.com
BBK Worldwide is a Newton, MA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
The Bailey Group is the largest pure employee benefits firm in Northeast Florida with over 70 full-time representatives, each dedicated to being an extension of their clients` HR departments.
"Eleven uses its proprietary technology platform to create first-of-a-kind protein therapeutics to address unmet needs for ophthalmic diseases. Proteins are able to modulate inflammatory cytokines, key targets in ocular disease that have been difficult to access with conventional therapeutic approaches. A significant untapped opportunity exists for protein therapeutics to address ophthalmic diseases, and Eleven is applying its advanced protein technology and expertise to develop innovative medicines for patients suffering from ocular diseases. Eleven`s team of industry veterans has deep experience in understanding protein science and biologic drug development, designing and conducting clinical trials and, most importantly, applying specific expertise in ophthalmic disease to create novel ocular therapeutics to treat unmet medical needs. Eleven has developed a proprietary pipeline of ophthalmic drug candidates derived from the company`s innovative AMP-Rx protein engineering technology. The company`s initial product candidates are focused on targeting inflammatory cytokines and key targets of ocular disease by blocking the cytokines and modulating the biological processes that drive ocular disease. Current pipeline opportunities include ocular surface diseases such as dry eye disease (DED) and allergic conjunctivitis (AC), and back of the eye diseases such as diabetic macular edema (DME) and uveitis. In addition, Eleven’s proprietary technology has been utilized to prolong the intravitreal half-life of our pipeline products. Beyond its internal drug development programs, Eleven works with collaborators, such as ThromboGenics, to apply its innovative protein therapeutic design capabilities to engineer and develop biotherapeutic products for additional therapeutic targets. EBI-005, Eleven`s lead product candidate, is a novel interleukin-1 (IL-1) receptor antagonist in Phase 3 clinical development as one of the first topically administered proteins for the treatment of DED and AC, two inflammatory diseases at the surface of the eye."
IMAC Regeneration Centers offers long-term solutions for chronic musculoskeletal conditions without surgery or opioids. This state-of-the-art medical treatment utilizes a combination of regenerative medicine and rehabilitation to prevent the most common unnecessary surgeries, including spinal fusion and laminectomy, and knee and hip replacements. Each of these surgeries require an opioid prescription 99.9% of the time, leading to a high risk of addiction and never returning to work.